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INTRODUCTION
Plasmacytoid monocytes (PM) represent a rare cell type in
human lymph nodes, and was originally referred to as plas-
macytoid T cells based on their plasma cell-like morphology,
expression of CD4, and localization in the T-dependent areas
of the lymph nodes (1-3). Subsequently, they were renamed
plasmacytoid monocytes because so-called plasmacytoid T
cells share major immunophenotypic features with cells of
the mononuclear-phagocytic system (4, 5).
PM in the lymph nodes is increased in certain conditions,
such as Kikuchi’s lymphadenitis, Castleman’s disease, and
Hodgkin’s disease (4, 6, 7). Tumorous proliferations of PM are
very rare. Less than 10 cases have been reported and they were
seen almost exclusively in lymph nodes. Interestingly, reported
cases previously were all associated with myeloproliferative
disease that usually had a monocytic component (8-10).
Immunophenotypic characteristics of reactive or neoplastic
PMs are consistent expressions of CD4, CD43, CD45, CD68,
and HLA-DR with weak expression of CD10 (8, 9). Other
markers associated with T, B, and myeloid cells, and mono-
cytes are mostly negative. Expression of CD56 in PM has not
been given much attention except recent two reports that
described PMs associated with CD56+ chronic myelomono-
cytic leukemia and cutaneous CD4+CD56+CD68+ neo-
plasm, respectively (10, 11).
Herein, we report a novel CD45RB+CD4+CD68+CD10+
CD56+ malignant neoplasm of the lymph node, which is most
consistent with PM. However the tumor cells weakly expressed
cCD3, which has never been described in PM. 
CASE REPORT
Clinical History
A 22-yr-old male patient was admitted with multiple lym-
phadenopathy of the inguinal, cervical, and preauricular lymph
nodes, the largest of which measured 4 cm in diameter. A
computed tomographic scan of the abdomen revealed diffuse
hepatosplenomegaly and enlarged paraaortic, common iliac,
and external iliac lymph nodes. Peripheral blood findings were
hemoglobin (Hb) 15.3 g/dL, and white blood cells (WBC) 7.4
×103/ L with normal differential counts except for increased
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CD4+CD56+CD68+ Hematopoietic Tumor of Probable Plasmacytoid
Monocyte Derivation with Weak Expression of Cytoplasmic CD3 
Hematopoietic neoplasm coexpressing CD4 and CD56 includes a subset of acute
myeloid leukemia with myelomonocytic differentiation, plasmacytoid monocyte
tumor, and other immature hematopoietic neoplasms of undefined origin. Herein,
we report a CD4+CD56+CD68+ hematopoietic tumor that was thought to be a tumor
of plasmacytoid monocytes. This case is unique in the absence of accompanying
myelomonocytic leukemia and the faint expression of cCD3 on the tumor cells. The
patient was a 22-yr old man presented with multiple lymphadenopathy and an
involvement of the bone marrow. Tumor cells were large and monomorphic with an
angulated eosinophilic cytoplasm of moderate amount. Nuclei of most tumor cells
were eccentric and round with one or two prominent nucleoli. Rough endoplasmic
reticulum was prominent in electron microscopic examination. Tumor cells expressed
CD4, CD7, CD10, CD45RB, CD56, CD68, and HLA-DR and were negative for CD1a,
CD2, sCD3, CD5, CD13, CD14, CD20, CD33, CD34, CD43, CD45RA, TIA-1, S-100,
and TdT. cCD3 was not detected in the immunostaining using paraffin tissue, but
was faintly expressed in flow cytometry and immunostaining using a touch imprint
slide. T-cell receptor gene rearrangement analysis and EBV in situ hybridization
showed negative results. Cytochemically, myeloperoxidase, Sudan black B, and
alpha naphthyl butyrate esterase were all negative. 
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monocytes (8.2%). The level of LDH (676 IU/L) increased.
The bone marrow was positive. After biopsy of the cervical
lymph node, he received one cycle of cyclophosphamide, dox-
orubicin, vincristine, prednisone (CHOP) chemotherapy with-
out response. Then high dose CHOP chemotherapy was given,
which attained complete remission. Subsequently the patient
underwent peripheral blood stem cell transplantation, however,
the tumor recurred in the bone marrow four months later. 
Pathologic Findings 
The biopsy of the cervical lymph node showed effacement
of nodal architecture by diffuse infiltration of monomorphic
tumor cells that were medium to large size with an angulated
eosinophilic cytoplasm of moderate amount. Nuclei of most
tumor cells were eccentric and round with one or two promi-
Fig. 1. Lymph node showing diffuse infiltration of tumor cells and
some starry-sky macrophages (H&E, ×100).
Fig. 2. Medium- to large-sized tumor cells with eccentric position of
nuclei and occasional prominent nucleoli (H&E, ×400). 
Fig. 3. Tumor cells in bone marrow smear exhibit eccentrically lo-
cated nuclei with  prominent Golgi zone (Giemsa, ×1,000). 
Fig. 4. Immunostaining with CD45 antibody. Note the weak stain-
ing of tumor cells compared to small reactive lymphocytes (arrow)
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nent nucleoli. Those cytologic features were reminiscent of
plasma cells or tumor cells of plasmacytoid immunoblastic
lymphoma. Some tumor cells showed slightly irregular nucleus
without conspicuous nucleoli. There were frequent mitotic
figures with many phagocytosing histiocytes between tumor
cells, imparting a starry sky appearance (Fig. 1, 2).
The bone marrow aspiration smear with trephine biopsy
showed medium- to large-sized tumor cells accounting for
57.6% of all nucleated cells (Fig. 3). Erythroid and granulo-
cytic precursors were rare with normal number of megakaryo-
cytes.
Immunohistochemical Findings
Paraffin section immunohistochemistry of the lymph
node showed that tumor cells were positive for leukocyte com-
mon antigen, CD56 (Monosan, The Netherlands) and CD68
(KP1) (DAKO, Denmark); negative for CD20 (DAKO, Den-
mark), polyclonal CD3 (DAKO, Denmark), TIA-1 (Coulter,
Hialeah, FL), S-100 (Dako, Denmark), CD1a (Novocastra,
U.K.), CD43 (Dako, Denmark), CD45RA (Dako, Den-
mark), and TdT (DAKO, Denmark) (Fig. 4-6). Polyclonal
CD3 immunostaining on touch imprint slide of bone mar-
row showed weak positivity of tumor cells (Fig. 7). 
Cytochemical Stains of Bone Marrow Smear
Tumor cells were negative for myeloperoxidase, Sudan black
B, and alpha naphthyl butyrate esterase and stained posi-
tively for PAS in block pattern.
Flow Cytometric Analysis
Flow cytometric analysis of bone marrow aspiration speci-
men was performed. PermaCyte-FPTM WBL3010 kit (Bio-
Ergonomics, MN, U.S.A.) was used for analysis of cytoplas-
mic CD3 expression. There was lymphoid light scatter with
dim to moderate CD45 expression which included 3% CD33+
cells, 3% CD13+ cells, 3% CD14+ cells, 25% CD7+ cells, 1%
CD5+ cells, 1% CD2+ cells, 11% CD19+ cells, 40%
Fig. 5. Immunostaining with anti-CD68 antibody. Almost all tumor
cells are positive (×250).
Fig. 6. Immunostaining with polyclonal anti-CD3 antibody using
paraffin-embedded section; the reactive T cells (arrow) are positive,
whereas the tumor cells are negative (×400).
Fig. 7. Immunostaining with polyclonal anti-CD3 antibody using
touch imprint slide; the reactive T cells are strongly positive, where-
as the tumor cells are weak positive (arrow) (×1,000). 836 Y.H. Ko, S.H. Kim, K. Park, et al.
CD10+ cells, 3% TdT+ cells, 4% CD34+ cells, 98% HLA-
DR+ cells, and 98% cCD3+ cells (Fig. 8, 9).
Cytogenetic Findings
Cytogenetic analyses were performed on bone marrow speci-
men. At diagnosis, 5 of 17 metaphases were abnormal, with
the following clonal abnormalities: t(6;8)(p21.1; q24.1), add
(10)(q22), monosomy 12, and a marker chromosome. The
tumor at recurrence showed more complex chromosomal
abnormality: 46, XY, add(1)(p36.1), add(3)(p12), add(4)(q21),
add(5)(q13), t(6; 8)(p21.1; q24.1), add(9)(p22), add(10)(q22),
-12, +mar[8]/45, idem,-13,-14[1]. 
EBV in Situ Hybridization Study
EBV in situ hybridization was performed using the fluo-
rescein-conjugated EBER1 and 2 oligonucleotides (Dako SA).
The result was negative.
Fig. 9. Flow cytometric study showing dim expression of CD10
and cytoplasmic expression of CD3. 
Fig. 8. Flow cytometric study of bone marrow aspirate. Tumor cells express CD45, CD4, CD56, and HLA-DR with dim expression of CD7. 
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Fig. 10. Electron micrograph showing abundant lamellated rough
endoplasmic reticulum in the cytoplasm (×5,000). 
G2A/G1
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T-Cell Receptor Gene Rearrangement Study
For polymerase chain reaction amplification of the T-cell
receptor (TCR) gamma locus, DNA was prepared by standard
proteinase K digestion and phenol/chloroform extraction. A
seminested PCR was performed as described previously (12).
No clonal rearrangement of TCR gene was demonstrated.
Electron Microscopic Study
Ultrastructurally, the tumor cells showed a round to oval
nucleus with condensed chromatin as a narrow rim at the nucle-
ar periphery. The cytoplasm contained a large amount of rough
endoplasmic reticulum and polyribosomes (Fig. 10).
DISCUSSION
The immunophenotype of positive CD4 and CD68 with
expression of CD10, and ultrastructural findings of abundant
polyribosomes and rough endoplasmic reticulum in the present
case do well fit into those of plasmacytoid monocyte described
in the literature (1-10).
CD4 is a 56-kDa glycoprotein, the expression of which is
best to define a subset of mature T-cells. CD4 expression is not
only limited to mature T cells, but also expressed on hemato-
poietic progenitors at various stages of lineage commitment
and has been observed on a number of human cell types includ-
ing megakaryocytes, eosinophils, monocytes, and dendritic
cells (13-15). On the other hand, CD68 represents a classical
immunohistochemical marker molecule for cells of the mono-
cyte/macrophage and dendritic cell system (16). But it also can
be detected in some natural killer cells,  / T cells, and acti-
vated CD4+ and CD8+ cells (17). Coexpression of CD4 and
CD68 without expression of other myelomonocytic markers
is characteristic of plasmacytoid monocytes. 
The lineage and the function of plasmacytoid monocytes
have remained an enigma. Recent immunological and hema-
tologic studies suggested that PM belongs to the mononu-
clear-phagocytic system, probably a precursor of dendritic
cells, which is specialized to support T-cell function (18). Rare
PM-like cells in the blood, which share morphological and
phenotypical features with PMs, express IL-3R (CD123)
and give rise to dendritic cells after being cultured with IL-3
and stimulated with CD40 ligand. These cells migrate to the
inflamed lymph nodes and promote the differentiation of type
2 T-helper cells. And they produce type 1 interferon that pro-
tects T-cells from antigen-induced cell death (19).
Tumorous proliferations of PM reported previously were
associated almost exclusively with myeloproliferative disorder,
especially myelomonocytic leukemia (5, 10). The occurrence
of myelomonocytic leukemia in the blood and of tumoral
growth of PM in the lymph node in a same patient suggests
that PMs and the associated myelomonocytic leukemia cells
represent the same neoplastic process (5). The present case was
not accompanied by myelomonocytic leukemia defined by
cytochemical and immunohistologic criteria. Instead, the tumor
cells weakly expressed cCD3 that was not detected in paraffin
tissue immunostaining, but detected in the flow cytometric
analysis and immunostaining using touch imprint smear,
suggesting that cCD3 existed at a level below for detection
after fixation and embedding. 
Aside from T or natural killer cell lymphoma/leukemia,
expression of cCD3 has never been described in other hema-
topoietic neoplasms including dendritic cell tumor. Dendritic
cells are derived from both myeloid dendritic cell developmen-
tal pathway and lymphoid hematopoietic progenitors (18, 20,
21). Plasmacytoid monocytes have characteristic of lymphoid
dendritic cells that are IL-3-dependent and express CD123
and initiate Th2 immune responses (18, 21). In the mouse,
development of thymic dendritic cells and that of T-lineage are
linked via a common precursor at an early stage of thymocyte
development (22). In humans, dendritic cells, T and B cells,
and natural killer cells could be differentiated from fetal marrow
CD34+CD10+CD45RA+ common hematopoietic precursor
cells (23). Moreover, conditional transformation of chicken
bone marrow progenitors with v-rel estrogen receptor fusion
gene induces dendritic cells expressing cCD3 and lymphoid
transcription factor GATA-3 (24). Therefore, the expression of
cCD3 in the plasmacytoid monocyte tumor appears to reflect
ontogenic relation between T cells and plasmacytoid monocytes
or “dedifferentiation” of neoplastic plasmacytoid monocyte
toward common T and dendritic cell progenitor. 
CD56 is an isoform of neural cell adhesion molecule involved
in cell-to-cell interactions and characteristically expressed on
normal NK cells and neoplasms of NK or NK-like T cell
origin. CD56 is a useful marker in detecting NK-related cells,
however, it is not lineage-specific, and seemingly aberrant
expression of CD56 also has been identified in a variety of
unrelated hematopoietic malignancies, including multiple
myeloma (25) and in 46% of acute myelogenous leukemia (26).
Coexpression of CD56 and CD4 can be seen in a subset of
acute myelogenous leukemia, especially in tumors with my-
elomonocytic differentiation (26). Recently a few reports
described certain groups of hematopoietic neoplasia that coex-
press CD56 and CD4. These tumors are TdT-negative blastic
NK cell lymphoma (27), cutaneous monomorphous CD4+
CD56+ large cell lymphoma (28), and agranular CD4+
CD56+ hematodermic neoplasm, which commonly involve
the skin at the time of presentation (29). Although these
tumors show slight difference in their immunophenotype,
they appear to be closely related.
TdT-negative blastic NK cell lymphoma described by
DiGiuseppe et al. (27) showed very similar immunopheno-
type with the present case and lacked cCD3 by immunohisto-
chemical stain using paraffin tissue and myelomonocytic mark-
ers by flow cytometry. The authors did not mention the
expression of CD68. Morphologically, their cases displayed blas-838 Y.H. Ko, S.H. Kim, K. Park, et al.
toid cytologic features, which were not observed in the pre-
sent case.
Cutaneous monomorphic CD4- and CD56-positive large
cell lymphomas reported by Nagatani et al. (28) shared similar
immunophenotypic findings with the present case, but the
tumor cells did not express CD68 (personal communication).
Histologically, non-blastoid cytologic findings with prominent
nucleoli were similar to the present case. 
Agranular CD4+CD56+ hematodermic neoplasm described
by Petrella et al. (29) is very similar to present case except
cutaneous presentation. The tumor consisted of CD4+ CD56+
CD68+HLA-DR+ small- or medium-sized cells with sever-
al small- to medium-sized nucleoli. Other lineage markers
including T, B, and NK cell markers were all negative. In the
subsequent study, the authors demonstrated expression of
CD123 in tumor cells and proposed that agranular CD4+
CD56+ hematodermic neoplasm could be the tumoral coun-
terpart of CD56+ PM-like cells (11). 
In conclusion, CD4+CD56+ neoplasms are heterogenous in
nature and include myelomonocytic leukemia, plasmacytoid
monocyte tumor, and other immature hematopoietic neoplasms.
Plasmacytoid monocyte tumor can be differentiated from other
CD4+CD56+ neoplasms by expression of CD68 and CD123
in the absence of myelomonocytic lineage markers, and electron
microscopic demonstration of abundant rough endoplasmic
reticulum would be an adjunctive to confirm the diagnosis. 
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